Jiangsu Hansoh Pharmaceutical Co., Ltd.
Clinical trials sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd., explained in plain language.
-
New hope for Tough-to-Treat lung cancer: first human trial begins
Disease control Recruiting nowThis is an early-stage study testing a new oral medication called HS-10504 for people with advanced non-small cell lung cancer (NSCLC) that has a specific genetic change (EGFR C797S mutation) and has worsened after previous targeted treatments. The main goals are to find a safe d…
Phase: PHASE1 • Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New pill aims to stop blood cell destruction in rare blood disease
Disease control Recruiting nowThis study is testing a new oral pill called HS-10542 for adults with PNH, a rare blood disease where the immune system destroys red blood cells. The goal is to see if the pill can safely control the disease and raise hemoglobin levels in people who still have active destruction …
Phase: PHASE1, PHASE2 • Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC